TriSalus Life Sciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023; Provides Revenue Guidance for the Full Year 2024
For the full year 2023, the company expects to report revenue of approximately $18.5 million. This represents growth of approximately 49% versus the full year 2022.
The company also provided revenue guidance for the Full Year 2024. The Company expects this strong momentum will continue and expects sales to grow in excess of 50% in 2024.